Literature DB >> 15547744

Cdx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas.

Kakuya Matsumoto1, Tsutomu Mizoshita, Tetsuya Tsukamoto, Naotaka Ogasawara, Akihiro Hirata, Yasuhiro Shimizu, Masakazu Haneda, Kenji Yamao, Masae Tatematsu.   

Abstract

We have previously reported that Caudal-related homeobox gene 2 (Cdx2) is a useful prognostic intestinal phenotypic marker for advanced gastric cancers. In this study, we examined Cdx2 expression and phenotype in pancreatic tumors. We evaluated 19 mucinous cystic tumors (MCTs), 17 intraductal papillary-mucinous tumors (IPMTs), and 41 invasive ductal carcinomas (IDCs) with regard to their gastrointestinal phenotype. The expression of Cdx2 was also assessed immunohistochemically. The lesions were phenotypically divided into 39 gastric (G type), 29 gastric and intestinal mixed (GI type), 3 intestinal (I type), and 6 null (N type) types, independent of the histopathological type. Most of the pancreatic tumors were thus judged to be the positive for gastric phenotypic members. Cdx2 nuclear staining demonstrated a close relation to the intestinal phenotypic expression in all three types (MCTs, IPMTs, and IDCs; p<0.05). In IDCs, Kaplan-Meier analysis of Cdx2 expression showed the Cdx2-positive group to have a significantly better outcome than their negative counterparts (p=0.015). In conclusion, our data suggest that Cdx2 might be necessary for intestinal phenotypic expression even in pancreatic tumor cells. In addition, Cdx2 expression in IDCs may be a novel prognostic marker for patient survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547744

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  New insights into the functions and localization of the homeotic gene CDX2 in gastric cancer.

Authors:  Lin-Hai Yan; Wei-Yuan Wei; Yu-Bo Xie; Qiang Xiao
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

2.  Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome.

Authors:  Qing-Long Li; Zhu-Lin Yang; Jie-Qiong Liu; Xiong-Ying Miao
Journal:  Pathol Oncol Res       Date:  2011-01-08       Impact factor: 3.201

3.  Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis.

Authors:  Carman Man-Chung Li; Vasilena Gocheva; Madeleine J Oudin; Arjun Bhutkar; Shi Yun Wang; Saya R Date; Sheng Rong Ng; Charles A Whittaker; Roderick T Bronson; Eric L Snyder; Frank B Gertler; Tyler Jacks
Journal:  Genes Dev       Date:  2015-09-01       Impact factor: 11.361

4.  Utilization of CDX2 expression in diagnosing pancreatic ductal adenocarcinoma and predicting prognosis.

Authors:  Wenbin Xiao; Hong Hong; Amad Awadallah; Lan Zhou; Wei Xin
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

5.  Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

Authors:  Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

6.  Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.

Authors:  Poornima Bhat-Nakshatri; Chirayu P Goswami; Sunil Badve; George W Sledge; Harikrishna Nakshatri
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.